Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies-Reference-Cited by-同舟云学术

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

Published:2021-11 Issue:11 Volume:3 Page:e778-e788
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Boekel Laura,Steenhuis Maurice,Hooijberg Femke,Besten Yaëlle R,van Kempen Zoé L E,Kummer Laura Y,van Dam Koos P J,Stalman Eileen W,Vogelzang Erik H,Cristianawati Olvi,Keijzer Sofie,Vidarsson Gestur,Voskuyl Alexandre E,Wieske Luuk,Eftimov Filip,van Vollenhoven Ronald,Kuijpers Taco W,van Ham S Marieke,Tas Sander W,Killestein Joep,Boers Maarten,Nurmohamed Michael T,Rispens Theo,Wolbink Gertjan

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference28 articles.

1. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry;Gianfrancesco;Ann Rheum Dis,2020

2. Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases;Furer;RMD Open,2021

3. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis;Hua;Arthritis Care Res (Hoboken),2014

4. Immunogenicity and safety of influenza vaccination in systemic lupus erythematosus patients compared with healthy controls: a meta-analysis;Liao;PLoS One,2016

5. Immunogenicity of the influenza vaccine in multiple sclerosis patients: a systematic review and meta-analysis;Nguyen;Mult Scler Relat Disord,2021

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 and multiple sclerosis: challenges and lessons for patient care;The Lancet Regional Health - Europe;2024-09

2. Anti-SARS-CoV-2 mRNA vaccination among patients living with SLE in Sweden: Coverage and clinical effectiveness;Lupus;2024-08-12

3. Duration of Postvaccination Neutralizing Antibodies to SARS‐CoV‐2 and Medication Effects: Results from the Safety and Immunogenicity of COVID‐19 Vaccination in Systemic Immune‐Mediated Inflammatory Diseases Cohort Study;ACR Open Rheumatology;2024-07

4. A Case Report and Literature Review of a Triple-Vaccinated, Rituximab-Treated Systemic Lupus Erythematosus patient with COVID-19 pneumonia;ARP Rheumatology;2024-06-30

5. Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases;JCI Insight;2024-06-04